Weekly Digest
April 27 – April 26, 2026 · 7 stories
The week's biggest signal is that the AI arms race is now a two-front war: OpenAI launched GPT-5.5 to reassert frontier dominance on April 23, and DeepSeek countered the very next day with an open-source V4 family trained entirely on Chinese hardware — a pointed reminder that export controls have not slowed China's pace. Meanwhile, the money is following the machines: Tesla is tripling capex to fund humanoid robots and robotaxis, and Merck is spending $6.7 billion to buy its way into the GLP-1 weight-loss race. Across healthcare, the contrast is stark — a landmark free gene therapy for deaf children on one end, and a 26% ACA premium spike pushing patients into bare-bones coverage on the other.
OpenAI released GPT-5.5 on April 23, positioning it as the company's smartest and most action-oriented model to date. The model matches GPT-5.4's per-token latency while delivering major gains in agentic coding, computer use, and multi-step research — and is already rolling out to Plus, Pro, Business, and Enterprise users across ChatGPT and Codex.
Chinese AI lab DeepSeek dropped preview versions of V4-Pro (1.6T total params, 49B active) and V4-Flash (284B total, 13B active) on April 24, both open-source and trained on Huawei Ascend 950 chips. The models beat all current open-source competitors in math, STEM, and coding benchmarks while rivaling closed-source frontier models — and introduce cost-effective 1M-token context windows.
On its Q1 2026 earnings call, Tesla raised full-year capital expenditure guidance to roughly $25 billion — triple prior years — earmarked for six factory ramps, Optimus humanoid production starting in late July, an Austin chip fab, and robotaxi expansion to a dozen states by year-end. Shares initially popped 4% on a free-cash-flow beat before giving back gains as investors digested the spending plans.
The Hart-Scott-Rodino waiting period expired on April 24 with no objections, clearing the path for Merck's $6.7 billion acquisition of Terns Pharmaceuticals at $53 per share. The deal gives Merck a pipeline in liver disease, obesity, and metabolic conditions — a direct move to compete with Novo Nordisk and Eli Lilly in the red-hot GLP-1 market.
Regeneron's Otarmeni received accelerated FDA approval on April 23 as the first-ever gene therapy for OTOF-related hereditary deafness, a condition affecting about 50 U.S. newborns per year. In trials, 80% of evaluable patients experienced improved hearing after a single surgical dose — and Regeneron will provide the therapy for free to all U.S. patients.
A KFF analysis found ACA Marketplace insurers raised gross premiums an average of 26% in 2026, costing consumers roughly $780 more per year. The sticker shock is reshaping enrollment patterns: in Missouri, nearly half of enrollees shifted to bronze-tier plans — the cheapest but highest-deductible option — after silver plans dominated in 2025.
Canadian enterprise AI company Cohere announced plans to acquire Germany's Aleph Alpha, forming a transatlantic partnership aimed at capturing European enterprise demand for sovereign, on-premises AI. The deal pairs Cohere's production-grade language models with Aleph Alpha's deep ties to European government and industrial customers.